Absence of Novel CYP4F2 and VKORC1 Coding Region DNA Variants in Patients Requiring High Warfarin Doses

Por Burmester, James K., Berg, Richard L., Glurich, Ingrid, Yale, Steven H., Schmelzer, John R., Caldwell, Michael D.
Publicado em 2011

Reinitiating Warfarin: Relationships Between Dose and Selected Patient, Clinical and Hospital Measures

Por Leonhard, Lucas G., Berg, Richard L., Burmester, James K., Mazza, Joseph J., Schmelzer, John R., Yale, Steven H.
Publicado no Clin Med Res (2015)

Validity of Using Inpatient and Outpatient Administrative Codes to Identify Acute Venous Thromboembolism: The CVRN VTE Study

Por Fang, Margaret C., Fan, Dongjie, Sung, Sue Hee, Witt, Daniel M., Schmelzer, John R., Steinhubl, Steven R., Yale, Steven H., Go, Alan S.
Publicado no Med Care (2017)

Evaluation of Genetic Factors for Warfarin Dose Prediction

Por Caldwell, Michael D., Berg, Richard L., Zhang, Kai Qi, Glurich, Ingrid, Schmelzer, John R., Yale, Steven H., Vidaillet, Humberto J., Burmester, James K.
Publicado em 2007

CYP4F2 genetic variant alters required warfarin dose

Por Caldwell, Michael D., Awad, Tarif, Johnson, Julie A., Gage, Brian F., Falkowski, Mat, Gardina, Paul, Hubbard, Jason, Turpaz, Yaron, Langaee, Taimour Y., Eby, Charles, King, Cristi R., Brower, Amy, Schmelzer, John R., Glurich, Ingrid, Vidaillet, Humberto J., Yale, Steven H., Qi Zhang, Kai, Berg, Richard L., Burmester, James K.
Publicado em 2008